JP4664074B2 - Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド - Google Patents

Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド Download PDF

Info

Publication number
JP4664074B2
JP4664074B2 JP2004543449A JP2004543449A JP4664074B2 JP 4664074 B2 JP4664074 B2 JP 4664074B2 JP 2004543449 A JP2004543449 A JP 2004543449A JP 2004543449 A JP2004543449 A JP 2004543449A JP 4664074 B2 JP4664074 B2 JP 4664074B2
Authority
JP
Japan
Prior art keywords
group
compound
formula
product
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004543449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508079A (ja
JP2006508079A5 (https=
Inventor
アーサー ジー． タベラス，
ジャンファ チャオ，
ピューラカットル ジェイ． ビジュ，
ユーノング ユー，
ジャイ エス． ファイン，
ウィリアム ヒプキン，
シンシア ジェイ． アキ，
ジェイ． ロバート メリット，
ゲ リ，
ジョン ジェイ． バルドウィン，
ガイファ ライ，
ミンラン ウー，
エバン エー． ヘッカー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2006508079A publication Critical patent/JP2006508079A/ja
Publication of JP2006508079A5 publication Critical patent/JP2006508079A5/ja
Application granted granted Critical
Publication of JP4664074B2 publication Critical patent/JP4664074B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
JP2004543449A 2002-10-09 2003-10-07 Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド Expired - Fee Related JP4664074B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41737102P 2002-10-09 2002-10-09
PCT/US2003/031707 WO2004033440A1 (en) 2002-10-09 2003-10-07 Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010197184A Division JP2010270151A (ja) 2002-10-09 2010-09-02 Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド

Publications (3)

Publication Number Publication Date
JP2006508079A JP2006508079A (ja) 2006-03-09
JP2006508079A5 JP2006508079A5 (https=) 2010-10-21
JP4664074B2 true JP4664074B2 (ja) 2011-04-06

Family

ID=32094009

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004543449A Expired - Fee Related JP4664074B2 (ja) 2002-10-09 2003-10-07 Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド
JP2010197184A Withdrawn JP2010270151A (ja) 2002-10-09 2010-09-02 Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010197184A Withdrawn JP2010270151A (ja) 2002-10-09 2010-09-02 Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド

Country Status (15)

Country Link
US (2) US20040186142A1 (https=)
EP (1) EP1551818B1 (https=)
JP (2) JP4664074B2 (https=)
CN (1) CN1720240B (https=)
AR (1) AR043052A1 (https=)
AT (1) ATE422203T1 (https=)
AU (1) AU2003288922A1 (https=)
CA (1) CA2501535A1 (https=)
DE (1) DE60326080D1 (https=)
ES (1) ES2321186T3 (https=)
MX (1) MXPA05003867A (https=)
MY (1) MY139601A (https=)
PE (1) PE20040570A1 (https=)
TW (1) TW200413342A (https=)
WO (1) WO2004033440A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20040053953A1 (en) * 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
MY139601A (en) 2002-10-09 2009-10-30 Schering Corp Thiadiazoledioxides and thiadiazoleoxides as cxc-and cc-chemokine receptor ligands
WO2004037804A1 (en) * 2002-10-22 2004-05-06 Oscotec Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
UY28538A1 (es) * 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
MXPA06007076A (es) * 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
CA2550540A1 (en) 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
WO2005113534A2 (en) * 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2005118609A2 (en) * 2004-05-26 2005-12-15 California Institute Of Technology Small molecule stimulators of neuronal growth
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
GB0510140D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
JP2009500328A (ja) * 2005-06-29 2009-01-08 シェーリング コーポレイション Ｃｘｃ−ケモカインレセプターリガンドとしての５，６−ジ−置換オキサジアゾロピラジンおよびチアジアゾロピラジン
MX2008000366A (es) * 2005-06-29 2008-03-07 Schering Corp Oxadiazoles di-sustituidos como ligandos del receptor cxc-quimiocina.
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR061829A1 (es) * 2006-07-07 2008-09-24 Schering Corp Ciclobuten-1, 2-dionas 3,4-di sustituidas como ligandos de receptores de quimiocinas cxc
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
WO2012148547A1 (en) * 2011-02-24 2012-11-01 The Schepens Eye Research Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
US8865723B2 (en) 2012-10-25 2014-10-21 Tetra Discovery Partners Llc Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
CN103724304B (zh) * 2013-12-24 2016-08-17 定陶县友帮化工有限公司 5-溴苯并呋喃的制备方法
CN103787956B (zh) * 2014-01-20 2016-03-30 上海医药工业研究院 用于制备泊马度胺的中间体的制备方法
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US11066488B2 (en) 2017-06-20 2021-07-20 Dow Global Technologies Llc Biaryl phenoxy group IV transition metal catalysts for olefin polymerization
GEP20237476B (en) * 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN109970588B (zh) * 2019-03-14 2024-03-08 武汉南望环保技术研究有限责任公司 一种无毒耐久型防污涂料及其制备方法
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN116854642A (zh) * 2022-03-26 2023-10-10 重庆博腾制药科技股份有限公司 一种（s）-2-哌嗪乙腈及其盐酸盐的制备方法
BG67727B1 (bg) 2022-04-04 2025-05-15 "Мицар Иновейшън" ООД Пан-хемокинови антагонисти за използване при превенция и намаляване на метастази при рак

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3115496A (en) * 1963-05-13 1963-12-24 Upjohn Co Certain 3, 4-disubstituted-1, 2, 5-thiadiazole-1, 1-dioxides and their preparation
US3115495A (en) * 1963-05-13 1963-12-24 Upjohn Co Certain 3, 4-diaryl-delta2-1, 2, 5-thiadiazoline-1, 1-dioxides and their preparation
DE1669798A1 (de) 1966-07-28 1971-08-26 Huels Chemische Werke Ag Verfahren zum Stabilisieren markomolekularer Polyacetale
CS214745B2 (en) * 1976-08-28 1982-05-28 Huels Chemische Werke Ag Shaped and non-shaped products from plastic materials
DK160611C (da) 1979-09-04 1991-09-16 Bristol Myers Squibb Co Analogifremgangsmaade til fremstilling af 3,4-disubstituerede 1,2,5-thiadiazol-1-oxider og -1,1-dioxider
DE3175201D1 (en) 1980-04-30 1986-10-02 Merck & Co Inc Aminothiadiazoles as gastric secretion inhibitors
US4394508A (en) * 1980-06-07 1983-07-19 Bristol-Myers Company Chemical compounds
US4510309A (en) * 1981-03-03 1985-04-09 Bristol-Myers Company Histamine H2 -antagonists
IE53068B1 (en) 1981-06-15 1988-05-25 Merck & Co Inc Diamino isothiazole-1-oxides and -1,1-dioxides as gastic secretion inhibitors
JPS5927880A (ja) 1982-07-08 1984-02-14 グラクソ・グル−プ・リミテツド 複素環式誘導体、その製法及びそれらを含む医薬組成物
FI832519A7 (fi) * 1982-07-12 1984-01-13 Bristol Myers Co Farmaseuttisia menetelmiä ja koostumuksia.
US4863936A (en) * 1982-12-14 1989-09-05 Smith Kline & French Laboratories Limited 3,5-Substituted-2-pyridyl-alkylaminocyclobutenediones having histamine h1 -antagonist activity
AU2222083A (en) * 1982-12-14 1984-06-21 Smith Kline & French Laboratories Limited Pyridine derivatives
JO1279B1 (en) * 1982-12-23 1985-04-20 جون ايف روبرت Pyridine derivatives
DE3309655A1 (de) * 1983-03-17 1984-09-20 Bayer Ag, 5090 Leverkusen 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4497810A (en) * 1983-10-14 1985-02-05 Merck & Co., Inc. Thiatriazine dioxides as gastric anti-secretory agents
US4562184A (en) * 1984-04-02 1985-12-31 Merck & Co., Inc. Substituted-aminohydroxypropoxy-thiadiazoles, β-blocking compositions and use
JPS60255756A (ja) * 1984-06-01 1985-12-17 Ikeda Mohandou:Kk アミノアルキルフエノキシ誘導体
GB8501535D0 (en) * 1985-01-22 1985-02-20 Smith Kline French Lab Chemical compounds
HU198696B (en) 1987-01-20 1989-11-28 Nissan Chemical Ind Ltd Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components
JPH02256668A (ja) 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
US5206252A (en) * 1992-05-08 1993-04-27 American Home Products Corporation Thiadiazolyl-amino derivatives of benzopyrans and indanes
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
US5354763A (en) * 1993-11-17 1994-10-11 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5506252A (en) * 1993-11-17 1996-04-09 American Home Products Corporation Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones
US5550139A (en) * 1994-01-03 1996-08-27 The Wichita State University Serine protease inhibitors
US5466712A (en) * 1994-11-04 1995-11-14 American Home Products Corporation Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones
AU686896B2 (en) 1994-11-16 1998-02-12 American Home Products Corporation Diaminocyclobutene-3,4-diones
US5494925A (en) * 1994-12-02 1996-02-27 Sterling Winthrop Inc. 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
BR9807083A (pt) * 1997-01-23 2000-04-18 Smithkline Beckman Corp Antagonistas ao receptor de il-8
AU6250298A (en) 1997-01-30 1998-08-25 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
US5840764A (en) * 1997-01-30 1998-11-24 American Home Products Corporation Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones
AR015425A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
ATE224358T1 (de) 1998-10-02 2002-10-15 Neurosearch As Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
ATE284387T1 (de) 1998-10-08 2004-12-15 Smithkline Beecham Plc 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
US6376555B1 (en) * 1998-12-04 2002-04-23 American Home Products Corporation 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
EP1140792A1 (en) 1998-12-14 2001-10-10 American Home Products Corporation 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
CZ20012185A3 (cs) 1998-12-16 2001-10-17 Bayer Aktiengesellschaft Nové bifenylové sloučeniny a sloučeniny analogické bifenylovým sloučeninám, způsob jejich přípravy, farmaceutické prostředky a pouľití těchto sloučenin a prostředků jako antagonistů integrinu
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
JP2003512349A (ja) 1999-10-15 2003-04-02 デュポン ファーマシューティカルズ カンパニー ケモカイン受容体活性のモジュレーターとしてのベンジルシクロアルキルアミン
CA2386049A1 (en) 1999-10-15 2001-04-26 Daniel S. Gardner Bicyclic and tricyclic amines as modulators of chemokine receptor activity
AR033803A1 (es) * 2000-03-01 2004-01-07 Smithkline Beecham Corp Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
EP1265905A4 (en) 2000-03-01 2003-03-12 Smithkline Beecham Corp IL-2 RECEPTOR ANTAGONISTS
JP2003527360A (ja) 2000-03-14 2003-09-16 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
MXPA02011868A (es) * 2000-05-30 2003-04-10 Smithkline Beecham Corp Antagonistas de receptor de interleucina 8.
US6395762B1 (en) * 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US20040048897A1 (en) * 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
DE60230722D1 (de) * 2001-01-16 2009-02-26 Smithkline Beecham Corp Il-8-rezeptor-antagonisten
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
RU2003126913A (ru) * 2001-02-02 2005-03-10 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс
PL208928B1 (pl) 2001-04-16 2011-06-30 Pharmacopeia 3, 4-di-podstawione cyklobuten-1, 2-diony jako ligandy receptora CXC chemokiny
US7132445B2 (en) * 2001-04-16 2006-11-07 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
JP2005505595A (ja) * 2001-10-12 2005-02-24 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物
US6878709B2 (en) * 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
US20040053953A1 (en) * 2002-03-18 2004-03-18 Schering Corporation Treatment of chemokine mediated diseases
MY139601A (en) 2002-10-09 2009-10-30 Schering Corp Thiadiazoledioxides and thiadiazoleoxides as cxc-and cc-chemokine receptor ligands
MXPA06007076A (es) * 2003-12-19 2006-08-31 Pharmacopeia Drug Discovery Tiadiazoles como ligandos del receptor cxc y cc-quimiocina.
CA2550540A1 (en) * 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands

Also Published As

Publication number Publication date
PE20040570A1 (es) 2004-08-30
US20040186142A1 (en) 2004-09-23
HK1072432A1 (en) 2005-10-28
EP1551818A1 (en) 2005-07-13
AR043052A1 (es) 2005-07-13
CA2501535A1 (en) 2004-04-22
US20070264230A1 (en) 2007-11-15
EP1551818B1 (en) 2009-02-04
JP2006508079A (ja) 2006-03-09
JP2010270151A (ja) 2010-12-02
DE60326080D1 (en) 2009-03-19
TW200413342A (en) 2004-08-01
CN1720240A (zh) 2006-01-11
CN1720240B (zh) 2010-10-27
ES2321186T3 (es) 2009-06-03
MXPA05003867A (es) 2005-11-23
WO2004033440A1 (en) 2004-04-22
WO2004033440A8 (en) 2005-06-02
MY139601A (en) 2009-10-30
ATE422203T1 (de) 2009-02-15
US7691856B2 (en) 2010-04-06
AU2003288922A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
JP4664074B2 (ja) Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾールジオキシドおよびチアジアゾールオキシド
JP2006508079A5 (https=)
JP4939229B2 (ja) Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのチアジアゾール
JP4851943B2 (ja) Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド
JP5294418B2 (ja) Ｃｘｃ−ケモカインレセプターリガンドとしての３，４−ジ−置換シクロブテン−１，２−ジオン
US6903131B2 (en) 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists
HK1087711B (en) Thiadiazoles as cxc- and cc- chemokine receptor ligands
HK1072432B (en) Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100602

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100609

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100902

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101215

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110106

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140114

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees